Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2019

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #1533

    Men de skal måske ikke have mere at betale 20% royalty af 😉

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #1534

      De kan jo bare købe butikken, så er de ude over det problem 😉

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #1535

        Just a moment...

        favicon

        (www.firstwordpharma.com)

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #1536

          Ved hvad Novo roder med angående DuoBody?

          1 Reply Last reply
          0
          • P Offline
            P Offline
            peter12
            wrote on sidst redigeret af
            #1537

            Det har været oppe før 😉 https://medwatch.dk/secure/Medicinal___Biotek/article10899921.ece

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #1538

              Takker- mon det kun er dette område. De udvidede jo antallet af licenser sidste år

              1 Reply Last reply
              0
              • P Offline
                P Offline
                peter12
                wrote on sidst redigeret af
                #1539

                Det kunne vel i princippet også være diabetes, hvis de kan bremse det tidligt ? Mener jeg har set en artikel på et tidspunkt

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  peter12
                  wrote on sidst redigeret af
                  #1540

                  Der står lidt her https://www.houstonchronicle.com/news/health/article/Testing-for-antibodies-early-can-delay-or-prevent-6717454.php

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #1541

                    BMS aflægger regnskab i dag, ser jeg. Kan hænde der kommer noget om diverse checkmate studier på CC.

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1542

                      comparables:

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #1543

                        REVLIMID® sales for the third quarter were $2,770 million, an increase of 13 percent year-over-year. U.S. sales were $1,902 million and international sales were $868 million, an increase of 14 percent and 11 percent year-over-year, respectively. REVLIMID® sales growth was driven primarily by the adoption of triplet therapy for myeloma resulting in increases in treatment duration and market share.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1544

                          POMALYST®/IMNOVID® sales for the third quarter were $664 million, an increase of 29 percent year-over-year. U.S. sales were $469 million and international sales were $195 million, an increase of 31 percent and 25 percent year-over-year, respectively. POMALYST®/IMNOVID® sales growth was driven primarily by the adoption of triplet therapy for myeloma resulting in increases in treatment duration and market share.

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #1545

                            They are happy about the partner Daratumumab 🙂

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #1546

                              😉

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #1547

                                for those that did not bother to read @gentogen 's link below, it clearly states "The ongoing combination trials in Multiple Myeloma and Lymphoma as well as combination trials with isatuximab and atezolizumab in solid tumors continue."

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  Bella1
                                  wrote on sidst redigeret af
                                  #1548

                                  Det lader til, at træet er ved at være rystet færdigt for denne gang 🙂

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #1549

                                    it is also end-of-month today, could see a good size auction

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #1550

                                      Horizon Therapeutics plc (Nasdaq: HZNP) today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab https://ir.horizontherapeutics.com/news-releases/news-release-details/integrated-clinical-trial-analyses-further-substantiate

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #1551

                                        Bella..En Genmab-Classic efterhånden. 🙂

                                        1 Reply Last reply
                                        0
                                        • H Offline
                                          H Offline
                                          hspinvest
                                          wrote on sidst redigeret af
                                          #1552

                                          Så gik GMAB i usa i Plus, mon ikke det sker med DK versionen også inden snart 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger